These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15464424)

  • 61. The peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and type 2 diabetes in an Arab population.
    Wakil SM; Al-Rubeaan K; Alsmadi O; Imtiaz F; Carroll P; Rajab M; Al-Katari S; Al-Katari M; Meyer BF
    Diabetes Care; 2006 Jan; 29(1):171-2. PubMed ID: 16373923
    [No Abstract]   [Full Text] [Related]  

  • 62. Evaluating the role of LPIN1 variation in insulin resistance, body weight, and human lipodystrophy in U.K. Populations.
    Fawcett KA; Grimsey N; Loos RJ; Wheeler E; Daly A; Soos M; Semple R; Syddall H; Cooper C; Siniossoglou S; O'Rahilly S; Wareham NJ; Barroso I
    Diabetes; 2008 Sep; 57(9):2527-33. PubMed ID: 18591397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Integrating publicly available genome-wide association data to study the genetic basis of metabolically healthy obese and metabolically obese but normal-weight individuals.
    Loos RJ
    Diabetes; 2014 Dec; 63(12):4004-7. PubMed ID: 25414016
    [No Abstract]   [Full Text] [Related]  

  • 64. Prospective functional classification of all possible missense variants in PPARG.
    Majithia AR; Tsuda B; Agostini M; Gnanapradeepan K; Rice R; Peloso G; Patel KA; Zhang X; Broekema MF; Patterson N; Duby M; Sharpe T; Kalkhoven E; Rosen ED; Barroso I; Ellard S; ; Kathiresan S; ; O'Rahilly S; ; Chatterjee K; Florez JC; Mikkelsen T; Savage DB; Altshuler D
    Nat Genet; 2016 Dec; 48(12):1570-1575. PubMed ID: 27749844
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system.
    Sigmund CD
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):676-8. PubMed ID: 23486770
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency.
    Campeau PM; Astapova O; Martins R; Bergeron J; Couture P; Hegele RA; Leff T; Gagné C
    J Lipid Res; 2012 Sep; 53(9):1968-78. PubMed ID: 22750678
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phospholipid modifier PLAAT3 links defective PPARγ-dependent signaling to lipodystrophy.
    Nat Genet; 2023 Nov; 55(11):1790-1791. PubMed ID: 37919454
    [No Abstract]   [Full Text] [Related]  

  • 68. Identification and Characteristics of Novel Mutations in Nonsyndromic Monogenic Obesity.
    Shi P; Shi Y; Liu X; Wang S; Yuan J; Zhao W; Fang L; Wang R; Yan F; Xu C
    Adv Biol (Weinh); 2023 Aug; 7(8):e2300061. PubMed ID: 37083215
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Re: Recurrent Activating Mutations of PPARγ Associated with Luminal Bladder Tumors.
    Atala A
    J Urol; 2019 Nov; 202(5):869. PubMed ID: 31365313
    [No Abstract]   [Full Text] [Related]  

  • 70. Monogenic hypertension-a type of "curable" hypertension.
    Lu Y; Fan P; Hakonarson H; Hu A; Liu Y; Zhou X
    Sci Bull (Beijing); 2023 Apr; 68(7):657-660. PubMed ID: 36964086
    [No Abstract]   [Full Text] [Related]  

  • 71. Functional implications of genetic variation in human PPARgamma.
    Jeninga EH; Gurnell M; Kalkhoven E
    Trends Endocrinol Metab; 2009 Oct; 20(8):380-7. PubMed ID: 19748282
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.
    Agostini M; Schoenmakers E; Mitchell C; Szatmari I; Savage D; Smith A; Rajanayagam O; Semple R; Luan J; Bath L; Zalin A; Labib M; Kumar S; Simpson H; Blom D; Marais D; Schwabe J; Barroso I; Trembath R; Wareham N; Nagy L; Gurnell M; O'Rahilly S; Chatterjee K
    Cell Metab; 2006 Oct; 4(4):303-11. PubMed ID: 17011503
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genetic markers of cardiac autonomic neuropathy in the Kazakh population.
    Bekenova N; Sibagatova A; Aitkaliyev A; Vochshenkova T; Kassiyeva B; Benberin V
    BMC Cardiovasc Disord; 2024 May; 24(1):242. PubMed ID: 38724937
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antidiabetic potential of thiazolidinedione derivatives with efficient design, molecular docking, structural activity relationship, and biological activity: an update review (2021-2023).
    Sharma A; Kumar N; Gulati HK; Rana R; Jyoti ; Khanna A; Muskan ; Singh JV; Bedi PMS
    Mol Divers; 2024 Jan; ():. PubMed ID: 38253844
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A PPARγ/long noncoding RNA axis regulates adipose thermoneutral remodeling in mice.
    Zhang Z; Cui Y; Su V; Wang D; Tol MJ; Cheng L; Wu X; Kim J; Rajbhandari P; Zhang S; Li W; Tontonoz P; Villanueva CJ; Sallam T
    J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37909330
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients.
    El-Farahaty RM; Fouda O; El-Deasty A; El-Gilany AH; Saied N
    J Diabetes Metab Disord; 2023 Jun; 22(1):415-422. PubMed ID: 37255811
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evidence Linking
    Cirelli T; Nicchio IG; Bussaneli DG; Silva BR; Nepomuceno R; Orrico SRP; Cirelli JA; Theodoro LH; Barros SP; Scarel-Caminaga RM
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047733
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ASSOCIATION BETWEEN PRO12ALa POLYMORPHISM OF PPARγ2 GENE AND CORONARY ARTERY DISEASE IN IRANIAN POPULATION WITH TYPE TWO DIABETES MELLITUS.
    Saremi L; Lotfipanah S; Feizy F; Ghaffari ME; Babaniamansour S; Saltanatpour Z
    Acta Endocrinol (Buchar); 2022; 18(2):139-144. PubMed ID: 36212264
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS).
    Siddiqui S; Mateen S; Ahmad R; Moin S
    J Assist Reprod Genet; 2022 Nov; 39(11):2439-2473. PubMed ID: 36190593
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Review article: vascular effects of PPARs in the context of NASH.
    Guixé-Muntet S; Biquard L; Szabo G; Dufour JF; Tacke F; Francque S; Rautou PE; Gracia-Sancho J
    Aliment Pharmacol Ther; 2022 Jul; 56(2):209-223. PubMed ID: 35661191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.